Publicaciones en las que colabora con Antonio Fernández Nebro (76)

2024

  1. Diffuse alveolar hemorrhage in patients with systemic lupus erythematosus: data from the Spanish society of rheumathology Lupus Register (RELESSER)

    Rheumatology International, Vol. 44, Núm. 11, pp. 2445-2455

  2. Multidisciplinary consensus on the use of hydroxychloroquine in patients with systemic lupus erythematosus

    Reumatologia Clinica, Vol. 20, Núm. 6, pp. 312-319

  3. Personalized cardiovascular risk assessment in Rheumatoid Arthritis patients using circulating molecular profiles and their modulation by TNFi, IL6Ri, and JAKinibs

    Biomedicine and Pharmacotherapy, Vol. 173

  4. Rate of severe and fatal infections in a cohort of patients with interstitial lung disease associated with rheumatoid arthritis: a multicenter prospective study

    Frontiers in Immunology, Vol. 15

  5. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

  6. Seven-chain adaptive immune receptor repertoire analysis in rheumatoid arthritis reveals novel features associated with disease and clinically relevant phenotypes

    Genome Biology, Vol. 25, Núm. 1

2023

  1. Analysis of comorbidity in rheumatoid arthritis–associated interstitial lung disease: a nested case-cohort study

    Biomedicine and Pharmacotherapy, Vol. 157

2022

  1. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

    Seminars in Arthritis and Rheumatism, Vol. 52

  2. Clinical characteristics and risk factors associated with lymphoma in patients with systemic lupus erythematosus: a nationwide cohort study

    Rheumatology (Oxford, England), Vol. 62, Núm. 1, pp. 217-224

  3. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  4. Effectiveness and safety of tocilizumab in monotherapy in biologic-naïve and non-naïve patients with rheumatoid arthritis in a real-world setting

    Reumatologia Clinica, Vol. 18, Núm. 10, pp. 567-573

  5. Longitudinal analysis of blood DNA methylation identifies mechanisms of response to tumor necrosis factor inhibitor therapy in rheumatoid arthritis

    eBioMedicine, Vol. 80

  6. Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis–Associated Interstitial Lung Disease

    Biomedicines, Vol. 10, Núm. 7

2021

  1. Contributions of the lupus register of the Spanish Society of Rheumatology (RELESSER) to the knowledge of systemic lupus erythematosus in Spain

    Reumatologia Clinica, Vol. 17, Núm. 5, pp. 245-249

  2. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

  3. Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy

    BMC Musculoskeletal Disorders, Vol. 22, Núm. 1

  4. Late-onset versus early-onset systemic lupus: characteristics and outcome in a national multicentre register (RELESSER)

    Rheumatology (Oxford, England), Vol. 60, Núm. 4, pp. 1793-1803

  5. Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?

    Rheumatology (Oxford, England), Vol. 60, Núm. 11, pp. 5329-5336

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

  2. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality

    Lupus, Vol. 29, Núm. 12, pp. 1556-1565